Concert Genetics
Thorne most recently was CEO of MedSolutions, which he grew from start up to nearly $1 billion in revenue and more than $100 million in EBITDA. MedSolutions merged with CareCore in December 2014, to create eviCore, the leading Benefits Management organization in America, which reduces health care costs as a consequence of improving the quality of care patients receive.
Prior to his 17 year stent at MedSolutions, Thorne held a variety of executive roles in the managed care industry, including starting and running PBMs for Cigna, The Travelers and Aetna. Thorne received a bachelors degree in chemistry from the University of North Carolina at Chapel Hill, and an MBA from Wake Forest University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Concert Genetics
Genetic testing is the lynchpin of precision medicine, but the rapid pace of change in the market makes it enormously complex. Today, there are more than 75,000 unique genetic testing products on the market, and an average of 10 new products are added each day. This growth confounds the processes through which tests are ordered, resulted, billed and reimbursed. Founded in 2010 with a vision to simplify this complexity, Concert Genetics (formerly NextGxDx, Inc.) launched as a healthcare technology company dedicated to streamlining the genetic test selection, ordering, payment and management for clinicians, hospitals, laboratories and health plans. With a leading team of clinicians, researchers, data scientists and software engineers, Concert Genetics launched its proprietary solutions to enable end-to-end genetic testing management, from searching and comparing testing products, to tracking orders and results, to payment integrity and forecasting trends in pricing and utilization. Today, stakeholders across the healthcare system turn to Concert Genetics to better understand and navigate the rapid transformation to precision medicine that is underway.